Here is the latest news on Nucana PLC:
- Financial Update and Clinical Program Advances: Nucana reported its financial results for the year ending December 31, 2024, and provided updates on its clinical programs. The company highlighted promising data from its lead anti-cancer medicines, NUC-7738 and NUC-3373, showing significant tumor reductions and prolonged progression-free survival in patients with melanoma and advanced solid tumors1.
- Registered Direct Offering: NuCana priced a $7 million registered direct offering, issuing 10,845,985 American Depository Shares (ADSs) or pre-funded warrants at a price of $0.6454 per ADS. The proceeds will fund drug discovery and development programs, as well as general corporate purposes2.
- Shareholder Vote on Key Resolutions: NuCana called for a general meeting with shareholders to vote on resolutions including the subdivision and redesignation of ordinary shares, authorization for the board to allot shares, and the adoption of new articles of association. These resolutions are crucial for the company's financial strategies and operational flexibility3.
- Earnings Estimates: William Blair forecasted Q1 2026 earnings of ($0.01) per share for NuCana, with a consensus estimate for the full-year earnings at ($13.42) per share. Institutional investors have shown interest in NuCana, with several making changes to their positions4.
In conclusion, NuCana PLC has recently announced promising clinical trial results for its lead anti-cancer medicines, secured funding through a registered direct offering, and called for a shareholder vote on key resolutions. Analysts forecast a slight earnings per share for the upcoming quarter, indicating a focus on strategic financial planning as evidenced by the shareholder resolutions.